中文

← All funding rounds

BigHat Biosciences

United StatesProtein designSan Mateo, California, United StatesFounded 2019Private

Website · bighatbio.com ↗

Designs antibodies with machine learning tied to a fast automated wet lab (Milliner) that makes and tests designs; its lead drug BHB810 is in the clinic.

Disclosed total$169M
Rounds on record3
Latest round$75MSeries C · 2026-09-24
Last stated valuationNone stated
Investors named20
Research on record1highest level 4 · Tested in the physical world

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date202120222023202420252026$19M$75M$75MEvidencelevel of each research entry12345
Closed roundResearch entry, at its level

Latest round, Series C, 2026-09-24: the record then held no research entry for the company. The first research entry is dated 2026-10-27; the highest level so far is 4 (Tested in the physical world).

Rounds and research, on one timeline

  1. 2026-10-27
    Research

    Level 4 · Tested in the physical world

    BigHat and Anthropic improve two antibody leads over seven rounds, after finding one thermal measure did not measure what its name said

    A closed-loop lab optimises the number it is given, so a measure that stands in badly for what a drug needs cannot be rescued by a better model or more data. The gain here came from people and a model reading the instrument signal and changing the experiment, not from more rounds of search. Published lab-in-the-loop work mostly takes the reported assay value as a correct label; this campaign did not.

    Timeline entry →bighatbio.com ↗

  2. 2026-09-24Series C
    Round

    $75M

    For: advance BHB810 and BHB299 to clinical readouts; scale data generation

    Toward the clinicData generation

    Total raised to date $223M.

    Co-lead · DFJ GrowthCo-lead · Premji Invest ✓Catalio Capital Management ✓LG Technology VenturesAmgen VenturesEli Lilly and CompanyMerck Global Health Innovation FundAndreessen Horowitz ✓Sigmas Group8VC ✓Alexandria Venture InvestmentsDiscovery Ventures ✓GRIDS Capital ✓Intermountain VenturesQuadrille Capital ✓Section 32

    On the deal: Justin Kao (Partner, DFJ Growth); Marc Martin Casas (Vice President of Biotech and Healthcare, Premji Invest)

    Announced by the company · bighatbio.com ↗On the timeline →

  3. 2022-07-20Series B
    Round

    $75M

    For: scale Milliner and advance programs toward the clinic

    Wet labToward the clinic

    Total funding $100M after this round.

    Lead · Section 32Amgen VenturesBristol Myers SquibbQuadrille Capital ✓Andreessen Horowitz ✓8VC ✓AME Cloud VenturesGaingelsGRIDS Capital ✓

    On the deal: Andy Harrison (Managing Partner; board observer, Section 32); Philip Tagari (VP of Research, Amgen Ventures); Steve Kafka (Managing Partner, Section 32, joins the board)

    Announced by the company · bighatbio.com ↗

  4. 2021-02-10Series A
    Round

    $19M

    For: grow the team and platform, advance internal programs

    HiringModels and platform

    Lead · Andreessen Horowitz ✓8VC ✓AME Cloud VenturesInnovation Endeavors

    On the deal: Francisco Gimenez (Partner, 8VC); Vineeta Agarwala (General Partner, Andreessen Horowitz, joins the board)

    Announced by the company · bighatbio.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

On the investors' own sites

Investors that name this company on their own site, in a portfolio or their own announcement. A ✓ in a round marks the same investor.

Its investors also backed

Other companies on this page whose rounds name the same investor.